Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma

Tadahiro Nozoe, Mitsuhiro Yasuda, Masayuki Honda, Sadaaki Inutsuka, Daisuke Korenaga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background/Aims: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. Methodology: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. Results: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19; p=0.007 and p=0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p=0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of 17; p=0.0005). Conclusions: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.

Original languageEnglish
Pages (from-to)1422-1425
Number of pages4
JournalHepato-gastroenterology
Volume54
Issue number77
Publication statusPublished - Jul 1 2007

Fingerprint

Anti-Idiotypic Antibodies
Colorectal Neoplasms
Serum
Neoplasms
Lymphatic Metastasis
p53 Genes
Lymph Nodes
Enzyme-Linked Immunosorbent Assay
Carcinoma
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Nozoe, T., Yasuda, M., Honda, M., Inutsuka, S., & Korenaga, D. (2007). Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepato-gastroenterology, 54(77), 1422-1425.

Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. / Nozoe, Tadahiro; Yasuda, Mitsuhiro; Honda, Masayuki; Inutsuka, Sadaaki; Korenaga, Daisuke.

In: Hepato-gastroenterology, Vol. 54, No. 77, 01.07.2007, p. 1422-1425.

Research output: Contribution to journalArticle

Nozoe, T, Yasuda, M, Honda, M, Inutsuka, S & Korenaga, D 2007, 'Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma', Hepato-gastroenterology, vol. 54, no. 77, pp. 1422-1425.
Nozoe, Tadahiro ; Yasuda, Mitsuhiro ; Honda, Masayuki ; Inutsuka, Sadaaki ; Korenaga, Daisuke. / Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. In: Hepato-gastroenterology. 2007 ; Vol. 54, No. 77. pp. 1422-1425.
@article{4b26c4986d114265b42fcd616cba0b14,
title = "Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma",
abstract = "Background/Aims: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. Methodology: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. Results: Frequency of serum presence of anti-p53 antibodies was 47.2{\%} (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6{\%}, 12 of 17 and 94.1{\%}, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6{\%}, 3 of 17 and 68.4{\%}, 13 of 19; p=0.007 and p=0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p=0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7{\%}, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6{\%}, 3 of 17; p=0.0005). Conclusions: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.",
author = "Tadahiro Nozoe and Mitsuhiro Yasuda and Masayuki Honda and Sadaaki Inutsuka and Daisuke Korenaga",
year = "2007",
month = "7",
day = "1",
language = "English",
volume = "54",
pages = "1422--1425",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "77",

}

TY - JOUR

T1 - Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma

AU - Nozoe, Tadahiro

AU - Yasuda, Mitsuhiro

AU - Honda, Masayuki

AU - Inutsuka, Sadaaki

AU - Korenaga, Daisuke

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background/Aims: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. Methodology: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. Results: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19; p=0.007 and p=0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p=0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of 17; p=0.0005). Conclusions: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.

AB - Background/Aims: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. Methodology: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. Results: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19; p=0.007 and p=0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p=0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of 17; p=0.0005). Conclusions: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=34547643530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547643530&partnerID=8YFLogxK

M3 - Article

C2 - 17708268

AN - SCOPUS:34547643530

VL - 54

SP - 1422

EP - 1425

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 77

ER -